4 Dividend Stocks That Give You a Clean Taste

Published Mon, 16 Jan 2012 20:23 CET by DividendYields.org

Introduction
Since I like to take good care of my teeth, I use mouthwash after brushing. While gargling, I was annoyed that every time I screwed the cap back on the bottle of Listerine® (I drink from the cap, yes), a little bit of mouthwash dripped from the cap on the bottle and the shelf, making it all very sticky. The previous bottle of mouthwash I used was Elmex Sensitive. For some of you an unknown brand maybe, but they really did something very clever: they made a little drinking tube inside the cap! Lo and behold, no more mouthwash dripping out, no more sticky bottles!
What does this have to do with dividend investing? Well... nothing really. But it gave me the idea to take a look at the companies behind all those bottles of mouthwash and see how they're doing, dividend-wise. So here we go.

How to invest in a clean taste?
Since this website is about dividend investing, the focus will be on stocks paying out dividend. Luckily, most producers of mouthwash are well-known companies and listed on the New York Stock Exchange: Colgate Palmolive (NYSE: CL), GlaxoSmithKline (NYSE: GSK), Jonhson & Johnson (NYSE: JNJ) and Procter & Gamble (NYSE: PG). All companies except GlaxoSmithKline are also S&P 500 Dividend Aristocrats.

Colgate Palmolive
Colgate Palmolive is owner of the GABA Group, which produces Aronal, Elmex and Meridol mouth-/dental rinses in Therwil, Switzerland. Colgate Palmolive had a net income of USD 2.5 billion in the last 12 months and has paid uninterrupted dividends on its common stock since 1895 and increased payments to common shareholders every year for 48 years.

GlaxoSmithKline
GSK produces mouthwash under the name of Astring-O-Sol, made famous by model Joey Eastwood in the kissing booth TV commercial. GSK had a net income of GBP 3.3 billion (~USD 5 billion) in the last 12 months.
The graphs below show the Earnings Per Share (EPS) and Dividend Per Share of GSK.

GlaxoSmithKline EPS and Dividend per Share Graphs

Jonhson & Johnson
In 2006, Listerine® became a JNJ product with the acquiring of Pfizer Consumer Healthcare. Listerine® Antiseptic was created in 1879, making it the first-ever antiseptic mouthwash. JNJ is the world's sixth-largest consumer health company with a net income of USD 64 billion in the last 12 months. The JNJ stock has seen 49 consecutive years of dividend increases.

Procter & Gamble
Oral-B (since acquiring Gillette in 2005) and Scope are brands of mouthwash made by Procter & Gamble. P&G is the largest consumer goods company with a net income of USD 11.8 billion in 2011 and has paid uninterrupted dividends on its stock since 1890 and increased payments to shareholders every year for 54 years.

Name Dividend growth rate (5 years) EPS growth (5 years)
Colgate Palmolive 12.83% 12.17 USD
GlaxoSmithKline 8.12% -17.22 GBP
Jonhson & Johnson 10.60% 7.35 USD
Procter & Gamble 11.37% 10.18 USD


Disclosure: at the moment of writing, TopYields doesn't own any of the stocks mentioned.
Stock name Dividend Yield
Glaxosmithkline 6.85
Procter & Gamble 3.38
Johnson & Johnson 2.54
Colgate Palmolive 2.25

Articles featuring Glaxosmithkline (GSK):

Lanny's April Dividend Income Summary

One of the best months of dividend income to report. As dividend investors, we love the quarter ends, due to being the most popular month, as well as an even better month for those that have mutual funds and/or ETFs. The busy season is slowly slowing down, gosh I wish it would end, but dividend income always keeps me at least going for the time being. Dividend Income I received a total of $424.15 of dividend income in April. This is slightly up, but could have been even higher, but... Read more

50 Healthcare Top Yield Equities For April

Actionable Conclusions (1-10): Analysts Predicted 9.8% To 41.2% Net Gains For Top Ten Healthcare Equities By April 2019 Two of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the chart above). Thus, this yield-based forecast for Healthcare dogs as graded by Wall St. wizards proved 20% accurate. Projections based on estimated dividend amounts from $1000 invested in... Read more

5%+ Dividend Yield Portfolio: Bought The Dip (Feb. 2018 Review)

Outlook Volatility returned to the markets in February climaxing early in the month with the first 10% correction in years. In response, a record number of investors panicked and pulled $30.6 billion out of equity funds in one week (the largest ever amount of weekly based on records going back to 2004, according to analysts at Bank of America Merrill Lynch). However, within weeks, those losses had been largely trimmed and the month closed down about 5%. The only question that matters is:... Read more

Lanny's January Dividend Income Summary

Wow. Here we are again, everyone. The first month of the year has come to a close. 31 days have flown by and another month of dividend income has been received. As a CPA, this month has worn me down, to say the least. Thank the Lord that dividend income continues to fuel the portfolio to new heights and continues to march on when I am struggling for time, research and spending time with loved ones. January was a great start for dividend income and I am proud to present the results to the... Read more

5%+ Dividend Yield Portfolio: The Rising Tide Raises My Boat (Jan 2018 Review)

Outlook Picking up where 2017 left off, January 2018 saw the indexes shatter records for new highs resulting in one of the strongest Januarys of the last 50 years! It looks like the bulls aren’t done yet as the S&P 500 notched a 5.7% gain. It is not all roses though as gains continue to not be evenly distributed which creates both opportunities and traps for investors. The broad theme of growth stocks over value stocks continues to play out, but volatility from early February already... Read more